Gene or Genome – Page 5

Japan Wins Exemption for Generics in US-Japan Trade Deal

3 months ago talkbio0Tagged generic pharmaceuticals, Japan, semiconductor supply chains, tariff exemption, TNFRSF19 gene, Transplant Registry Unified Management Program, U.S.

Japan; US Trade Deal; generic pharmaceuticals; tariff exemption; semiconductor supply chains; Trump administration

Treeline Announces $200M Funding Boost, Moves Three Cancer Drugs into Clinic

3 months ago talkbio0Tagged BCL6 gene, cancer drugs, Clinical Trials, Degrader, EZH2 protein, human, Funding, Inhibitor, K-ras Oncogene, Lymphoma, Series, Solid Neoplasm, TLN-121, TLN-254, TLN-372, Treeline

Treeline Biosciences; cancer drugs; clinical trials; TLN-121; TLN-372; TLN-254; BCL6 degrader; KRAS inhibitor; EZH2 inhibitor; Series A funding; lymphoma; solid tumors

Amgen to Invest Over $600M in New Innovation Centre at California Headquarters

3 months ago talkbio0Tagged amgen, Automation, Biotechnology, California, Capital, Construction worker, digital tools, ELAVL2 gene, Incentives, innovation, innovation centre, Investments, Science, therapeutic development, Thousand Oaks

Amgen; innovation centre; science and innovation hub; Thousand Oaks; California; biotechnology; construction; automation; digital tools; therapeutic development; tax incentives; capital investment

Royalty Pharma Buys $885M Imdelltra Royalty Stake from BeOne

4 months ago talkbio0Tagged amgen, bispecific, DLL3, DLL3 gene, ES-SCLC, Imdelltra, Malignant neoplasm of lung, Royalty, Small cell carcinoma of lung, upfront

BeOne Medicines; Imdelltra; Amgen; Royalty Pharma; $885 million upfront; lung cancer; royalty deal; DLL3 bispecific; small cell lung cancer; ES-SCLC

Argenx’s Vyvgart Shows Positive Phase 3 Results in Seronegative Myasthenia Gravis

4 months ago talkbio0Tagged AChR-Ab, Adaptation, Argenx, expansion, Labels (device), LRP4 gene, Musk, Myasthenia Gravis, Phase 3, SERON, Seronegative, triple seronegative, United States Food and Drug Administration, Vyvgart

Vyvgart; Argenx; Phase 3; myasthenia gravis; seronegative; ADAPT SERON; AChR-Ab; MuSK+; LRP4+; triple seronegative; FDA label expansion

Trump Locks in 15% Pharmaceutical Tariff Rate for EU, Generic Drugs Exempted

4 months ago talkbio0Tagged 15%, brand-name drugs, EU, Evaluation, Generic Drugs, Sectioning technique, tariff, tariff exemption, TNFRSF19 gene, transatlantic trade, Trump administration

15% tariff; pharmaceuticals; EU; Trump administration; generic drugs; trade deal; tariff exemption; brand-name drugs; transatlantic trade; Section 232 investigation

CSL Announces Vaccine Unit Spin-Off and Major Workforce Cuts

4 months ago talkbio0Tagged cost-cutting, demerger, Seqirus, SMPX gene, strategic restructuring, Vaccines

CSL; Seqirus; vaccine spin-off; workforce reduction; demerger; strategic restructuring; biotech; cost-cutting

FDA Extends PDUFA Date for Regenxbio’s Hunter Syndrome Gene Therapy RGX-121

4 months ago talkbio0Tagged clemidsogene lanparvovec, Deferred, gene therapy, IDS gene, Infrequent, Mucopolysaccharidosis II, PDUFA, Regenxbio, RGX-121, United States Food and Drug Administration

FDA delay; PDUFA extension; Regenxbio; Hunter syndrome; clemidsogene lanparvovec; RGX-121; gene therapy; Mucopolysaccharidosis II; IDS gene; rare disease

Insmed Secures FDA Approval for First DPP1 Inhibitor in Lung Disease

4 months ago talkbio0Tagged Approved, brensocatib, Brinsupri, Bronchiectasis, CTSC gene, Inhibitor, Insmed, Lung diseases, United States Food and Drug Administration

Insmed; FDA approval; DPP1 inhibitor; Brensocatib; Brinsupri; bronchiectasis; lung disease

Insmed’s Brinsupri Receives First-Ever FDA Approval for Progressive Lung Disease

4 months ago talkbio0Tagged Approved, brensocatib, Brinsupri, Bronchiectasis, CTSC gene, Inhibitor, Insmed, Lung diseases, neutrophil-mediated disease, non-cystic fibrosis bronchiectasis, Progressive, United States Food and Drug Administration

Brinsupri; Insmed; FDA approval; non-cystic fibrosis bronchiectasis; bronchiectasis; DPP1 inhibitor; brensocatib; progressive lung disease; neutrophil-mediated disease; first-in-class